Related Experiment Video

Updated: May 21, 2025

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs
08:18

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

Published on: July 27, 2022

982

Solid Lipid Nanoparticles for the Management of Hypertension: Advancements and Challenges

Avinaba Das1, B H Jaswanth Gowda1, Umme Hani2

  • 1Department of Pharmaceutics, Yenepoya Pharmacy College & Research Centre, Yenepoya (Deemed to be University), Mangalore 575018, Karnataka, India.

Current Pharmaceutical Design
|March 20, 2025
PubMed

Insights

Solid lipid nanoparticles (SLNs) improve hypertension treatment by enhancing the bioavailability and efficacy of antihypertensive drugs. This nanotechnology offers a promising strategy to overcome limitations of conventional therapies for cardiovascular diseases.

Area of Science:

  • Nanotechnology and Pharmaceutical Sciences
  • Cardiovascular Medicine
  • Drug Delivery Systems

Background:

  • Hypertension is a major global health challenge and a leading risk factor for cardiovascular diseases (CVDs).
  • Conventional antihypertensive medications often suffer from poor bioavailability and limited efficacy.
  • Nanoparticles (NPs), particularly solid lipid nanoparticles (SLNs), present a novel approach to enhance drug delivery for hypertension management.

Purpose of the Study:

  • To review the pathophysiology of hypertension and the role of SLNs in drug delivery.
  • To explore the preparation techniques and pharmaceutical applications of SLNs.
  • To examine the potential of SLNs in improving the management of hypertension through enhanced drug properties.

Main Methods:

  • Review of existing literature on hypertension, SLNs, and drug delivery.
  • Discussion of SLN preparation methods and their characteristics.
  • Analysis of SLNs' impact on physicochemical properties of antihypertensive drugs.

Main Results:

  • SLNs enhance solubility, bioavailability, and provide sustained release of encapsulated antihypertensive drugs.
  • SLNs offer scalability and biological compatibility compared to other nanosystems.
  • SLNs demonstrate potential in optimizing hypertension treatment and improving patient outcomes.

Conclusions:

  • SLNs represent a promising strategy for overcoming limitations in conventional hypertension therapy.
  • Enhanced drug stability, bioavailability, and efficacy through SLNs can improve patient outcomes.
  • SLNs offer innovative possibilities for reducing the global burden of cardiovascular diseases.

Keywords:
Blood pressurecardiovascular diseasesdrug deliveryhypertension.lipid nanoformulationnanoparticles

More Related Videos

Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications08:19

Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications

Published on: November 17, 2015

17.0K
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

8.9K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
492
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
119
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
449
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
124
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
140
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.8K